immunosuppressive

[키워드] 1:1 accompany adjusted Admission Affair age analyst antibiotic antiviral therapy Arrhythmias blinded Breastfeeding breathing ambient air Care Child-Pugh score Chronic kidney disease city classical clinical clinical effectiveness Clinical improvement clinical sample clinical symptom clinically Coma Combination Comorbidity comparator Compliance conducted control arm control group Controlled clinical trial COVID-19 current Dammam data entry death deficiency defined diagnosed with COVID-19 dialysis discharge discharged disease disease onset dissemination drug ECMO effective sample size Efficacy Efficacy and safety eight element enrolled Enrollment evaluate Evidence experimental arm extracorporeal membrane oxygenation Faisal Favipiravir female G6PD Glucose-6-phosphate hereditary xanthinuria HIV hospital Hospital admission Hospitalized Hydroxychloroquine Hyperuricemia ICU admission Imam immunosuppressive in vitro include information Intervention intravenous fluid invasive ventilation investigator Jeddah King less limit Liver damage Major malignancy medication moderate multicenter Multicenter trial Myocardial infarction noninvasive nonpregnant number objective ongoing trial outcome oxygen saturation Palliative care participant Patient PCR pregnant primary endpoint prior diagnosis prognostic prolonged QT interval protocol QT interval randomised randomised controlled trial randomization Randomized receiving recruitment reference risk Sample size SARS-CoV-2 Saudi Arabia selected seven-category ordinal scale Standard Stratification study drug Study protocol subject supplemental oxygen Supportive treatment Symptom System tablets the patient therapeutic agent therapy transferred Treatment Trial ULN Urinary tract use of hydroxychloroquine vasopressor support ventricular viral infection Web website with COVID-19 xanthine
[DOI] 10.1186/s13063-020-04825-x PMC 바로가기 [Article Type] Letter